ADAMTS13 and thrombotic thrombocytopenic purpura: The clinical phenotype of TTP is no longer perceived as two ends of a spectrum represented by distinct acute and remission states, but a disease where resting ADAMTS13 levels may predict vascular health in the mid-long term for patients with congenital and immune-mediated TTP.